Matt Kapusta, uniQure CEO
In troubled Huntington’s space, uniQure’s gene therapy shows early promise
In randomized clinical trial data from a small number of patients, Dutch biotech uniQure shared that its gene therapy for Huntington …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
